Literature DB >> 7864512

Sex hormones in chronic systemic lupus erythematosus. Correlation with clinical and biological parameters.

J A Muñoz1, A Gil, J M López-Dupla, J J Vázquez, P González-Gancedo.   

Abstract

Sex hormones may play a major role in the pathogenesis and course of systemic lupus erythematosus (SLE). OBJECTIVE--To evaluate the immunoregulatory effect of gonadal steroids in SLE and their mechanisms of action, and to establish a correlation with the clinical and biological activity. DESIGN--Cross-sectional study of a cohort with SLE. SETTING--Outpatient SLE clinic. PATIENTS--27 patients with chronic SLE, 14 were fertile women, 8 postmenopausal women and 5 men. MEASUREMENT--Serum gonadotropins (FSH, LH), prolactin (PRL), progesterone (PG), testosterone (T), estradiol (E2) and total urinary estrogens (UE) were studied in SLE patients and in 35 healthy controls of similar age and sex. Blood and urine samples of several days of the study cycle were obtained for hormonal assay. RESULTS--An increased LH activity was observed in all groups of patients. There were no changes in serum T levels, but absence of steroid therapy increased their levels in fertile women. A decrease in E2 values in the fertile women was observed, but total UE was similar to those in controls. This suggests an alteration in intermediate estrogen metabolism. Men with SLE showed a higher levels in PG and UE than controls. Also, in both groups of women on steroid treatment, a decrease of PRL was observed compared to the controls. In the fertile women in luteal phase, there was a decrease in PG. In the fertile women with higher clinical activity in the midcycle phase, and those with higher biological activity in the luteal phase, a decrease in serum E2 was seen. CONCLUSIONS--Our results support the hypothesis that there is an alteration of intermediate metabolism of the estrogens and of the testosterone. As well, a lower production of PRL during steroid treatment, and a lower production of PG may be important contributing factors in immunomodulation of SLE. Mechanism for this action should be mediated through a stimulation of the gonadotropins as LH.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7864512

Source DB:  PubMed          Journal:  Ann Med Interne (Paris)        ISSN: 0003-410X


  5 in total

1.  Bromocriptine restores tolerance in estrogen-treated mice.

Authors:  E Peeva; C Grimaldi; L Spatz; B Diamond
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

2.  Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls.

Authors:  A M Jacobi; W Rohde; H D Volk; T Dörner; G R Burmester; F Hiepe
Journal:  Ann Rheum Dis       Date:  2001-03       Impact factor: 19.103

3.  Androgen receptor (CAG)n polymorphism and androgen levels in women with systemic lupus erythematosus and healthy controls.

Authors:  Ralitsa Robeva; Dobromir Tanev; Silvia Andonova; Georgi Kirilov; Alexey Savov; Milena Stoycheva; Analia Tomova; Philip Kumanov; Rasho Rashkov; Zlatimir Kolarov
Journal:  Rheumatol Int       Date:  2013-02-07       Impact factor: 2.631

4.  Prolactin modulates the naive B cell repertoire.

Authors:  Elena Peeva; Daniel Michael; James Cleary; Jeffrey Rice; Xian Chen; Betty Diamond
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

5.  17β-Estradiol protects against the progression of hypertension during adulthood in a mouse model of systemic lupus erythematosus.

Authors:  Emily L Gilbert; Keisa W Mathis; Michael J Ryan
Journal:  Hypertension       Date:  2013-12-23       Impact factor: 10.190

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.